Replies to post #371644 on Amarin Corp Plc (AMRN)

[sstyles]

In light of GSK v. Teva, I am not convinced generics can just come in and take half of the CV market even if they had supply.

Amarin could still bring suit later on....and one would think market share would be some indication of direct infringement. Hard for a judge or jury to deny that half of the market share is the CV indication.

[couldbebetter]

Dukesking, Whoever is working on the study of generic vs. branded
Vascepa could be used as a weapon to shut down generics. If such a
study shows issues with generic Vascepa (such as high oxidation rates)
my hope is that AMRN would aggressively use that info to get the FDA
to shut down the generics (unlikely unless Pfizer were pushing it.)
However, I would hope that KM would have the guts to advertise
the facts if they show generics being inferior. What is the FDA
going to do to us if they don't like the advertising? I don't care!
KM should be laying hardball in the US "if" he has the ammunition
to back him up. Besides just going after generic Vascepa I would
want a case to be made against generic Lovasa and dietary supplements
as well. (Again, with the right ammunition to back it up.)